全文获取类型
收费全文 | 64806篇 |
免费 | 4395篇 |
国内免费 | 890篇 |
专业分类
耳鼻咽喉 | 481篇 |
儿科学 | 1166篇 |
妇产科学 | 833篇 |
基础医学 | 3450篇 |
口腔科学 | 916篇 |
临床医学 | 7412篇 |
内科学 | 6445篇 |
皮肤病学 | 780篇 |
神经病学 | 5272篇 |
特种医学 | 1046篇 |
外科学 | 4709篇 |
综合类 | 13042篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 6228篇 |
眼科学 | 397篇 |
药学 | 9719篇 |
179篇 | |
中国医学 | 5451篇 |
肿瘤学 | 2561篇 |
出版年
2024年 | 213篇 |
2023年 | 1127篇 |
2022年 | 2236篇 |
2021年 | 2957篇 |
2020年 | 2961篇 |
2019年 | 2509篇 |
2018年 | 2288篇 |
2017年 | 2509篇 |
2016年 | 2807篇 |
2015年 | 2717篇 |
2014年 | 6792篇 |
2013年 | 6346篇 |
2012年 | 5497篇 |
2011年 | 5257篇 |
2010年 | 3879篇 |
2009年 | 2892篇 |
2008年 | 2689篇 |
2007年 | 2421篇 |
2006年 | 1949篇 |
2005年 | 1478篇 |
2004年 | 1166篇 |
2003年 | 963篇 |
2002年 | 769篇 |
2001年 | 625篇 |
2000年 | 566篇 |
1999年 | 403篇 |
1998年 | 341篇 |
1997年 | 311篇 |
1996年 | 249篇 |
1995年 | 224篇 |
1994年 | 203篇 |
1993年 | 160篇 |
1992年 | 131篇 |
1991年 | 110篇 |
1990年 | 115篇 |
1989年 | 111篇 |
1988年 | 90篇 |
1987年 | 92篇 |
1986年 | 90篇 |
1985年 | 186篇 |
1984年 | 255篇 |
1983年 | 211篇 |
1982年 | 235篇 |
1981年 | 207篇 |
1980年 | 161篇 |
1979年 | 160篇 |
1978年 | 112篇 |
1977年 | 77篇 |
1976年 | 78篇 |
1975年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2020,31(3):378-387
PurposeTo determine if cone-beam CT and digital subtraction angiography analysis of pelvic arterial anatomy has predictive value for radiation exposure and technical success of prostatic artery embolization (PAE).Materials and MethodsThis prospective, nonrandomized, single-center study included 104 consecutive patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Cone-beam CT was performed in 160/208 (76.9%) hemipelves to determine prostatic artery (PA) origin. Classification of pelvic arterial tortuosity was possible in 73/104 (70.2%) patients. Learning curves of 2 interventionalists who performed 86.5% of PAEs were analyzed.ResultsTortuosity of pelvic arteries was classified as mild in 25 (34.2%) patients median age 64 years, moderate in 40 (54.8%) patients median age 69 years, and severe in 8 (11.0%) patients median age 70 years (mild vs moderate, P = .002; mild vs severe, P = .019); median fluoroscopy times were 24, 36, and 46 minutes (P = .008, P = .023); median contrast volumes were 105, 122.5, and 142 mL (P = .029, P = .064); and bilateral PAE rates were 84.0%, 77.5%, and 62.5% (P = .437), respectively. PA origin from superior vesical artery was most frequent (27.5%) and showed higher dose area product (median 402.4 vs 218 Gy ∙ cm2, P = .033) and fluoroscopy time (median 42.5 vs 27 min, P = .01) compared with PA origin from obturator artery, which was least frequent. Interventionalist experience revealed significant impact on procedure times (median 159 vs 130 min, P = .006).ConclusionsTortuosity of pelvic arteries was more frequent in older patients and predicted worse technical outcomes of PAE. PA origin from obturator artery was associated with lower dose area product and fluoroscopy time, especially compared with PA origin from superior vesical artery. Interventionalist experience showed significant influence on technical outcome. 相似文献
3.
4.
5.
目的:探讨保妇康凝胶联合诺氟沙星治疗宫颈糜烂的临床效果。方法将100例宫颈糜烂患者根据随机数字表法分为观察组和对照组各50例。观察组给予保妇康凝胶和诺氟沙星联合治疗,对照组单独给予治糜灵栓治疗,比较两组患者临床症状的变化,并对临床疗效进行评价。结果观察组治愈率为86.00%,明显高于对照组的74.00%,临床症状评分改善较对照组明显,且其临床症状消失的时间短于对照组,差异均有统计学意义(P<0.05)。结论保妇康凝胶与诺氟沙星合用比治糜灵栓治疗宫颈糜烂效果更佳,且治愈时间上明显较优,值得临床上推广应用。 相似文献
6.
目的:探讨微波配合序贯扩肛治疗陈旧性肛裂的临床疗效。方法:选取陈旧性肛裂患者78例,随机分为对照组和治疗组,每组各39例。对照组患者采用后卫内括约肌部分切断治疗,治疗组患者采用微波配合序贯扩肛治疗。结果:观察组患者术中出血量、切口愈合时间均少于对照组(P<0.05),并发症发生率低于对照组(P<0.05)。结论:采用微波配合序贯扩肛治疗陈旧性肛裂,临床疗效显著。 相似文献
7.
8.
目的:分析糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效。方法:选取我院2017年1月—2019年1月收治的200例糖尿病视网膜病变合并黄斑水肿患者为研究对象,随机分为两组。对照组单独行激光治疗,观察组于对照组基础上联合复方血栓通胶囊治疗,对比两组临床疗效、治疗前后IL-6(白介素-6)、VEGF(血管内皮生长因子)、NOS(血清一氧化氮合成酶)水平变化情况。结果:对照组总有效率(68.00%,68/100)较观察组总有效率(98.00%,98/100)更高(P<0.05);与对照组对比,观察组治疗后NOS水平更高,IL-6、VEGF水平更低(P<0.05)。结论:糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效显著,值得推广。 相似文献
9.
10.